{
  "$schema": "folio-library-entry/v1",
  "id": "10665-352523",
  "blocks": [
    {
      "id": "library/10665-352523/blocks/prose-sec-front-matter",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Front matter",
      "pageStart": 1,
      "pageEnd": 7,
      "target": "../sections/sec-front-matter.md",
      "narrative": null,
      "content": "Module 5: Management \nof tuberculosis in children \nand adolescents\nWHO  \noperational \nhandbook on \ntuberculosis\nWHO \noperational \nhandbook on\u0003 \ntuberculosis\nModule 5: Management \nof tuberculosis in children \nand adolescents\nWHO operational handbook on tuberculosis. Module 5: management of tuberculosis in children and adolescents\nISBN 978-92-4-004683-2 (electronic version)\nISBN 978-92-4-004684-9 (print version)\n© World Health Organization 2022\nSome rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence \n(CC BY-NC-SA 3.0 IGO; https",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The front matter of the WHO operational handbook on tuberculosis, Module 5: management of TB in children and adolescents (2022), with the ISBN and licence page, citation, disclaimers and a table of contents covering screening, prevention, diagnosis, treatment, models of care, special situations and annexes.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352523/blocks/prose-sec-000",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Acknowledgements",
      "pageStart": 7,
      "pageEnd": 11,
      "target": "../sections/sec-000-acknowledgements.md",
      "narrative": null,
      "content": "Acknowledgements \nThis operational handbook was prepared by Sabine Verkuijl, Annemieke Brands, Kerri Viney and \nTiziana Masini, under the guidance of Farai Mavhunga and the overall direction of Tereza Kasaeva, \nDirector of the World Health Organization (WHO) Global Tuberculosis (TB) Programme.\nThe WHO Global TB Programme gratefully acknowledges the contributions of all experts who were \ninvolved in the production of the operational handbook. Unless otherwise specified, those listed below \nwork in the WHO Global TB Programme.\nChapter 1 (Introduction) was written by Annemieke Brands, with contri",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Acknowledges the WHO Global TB Programme staff who wrote each chapter of the child and adolescent TB handbook, the many external contributors and reviewers, and funding from Unitaid, USAID and the US CDC.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352523/blocks/prose-sec-001",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Abbreviations",
      "pageStart": 11,
      "pageEnd": 15,
      "target": "../sections/sec-001-abbreviations.md",
      "narrative": null,
      "content": "Abbreviations\nABC\t\nabacavir\nAIDS\t\nacquired immunodeficiency syndrome\nALT\t\nalanine aminotransferase\nAm\t\namikacin\namoxiclav\t\namoxicillin with clavulanic acid (also known as co-amoxiclav)\naOR\t\nadjusted odds ratio\nART\t\nantiretroviral therapy\nAST\t\naspartate aminotransferase\nAZT\t\nzidovudine\nB (or Bdq)\t\nbedaquiline\nBCG\t\nbacille Calmette-Guérin\nCaP-TB\t\nCatalyzing Pediatric Tuberculosis Innovation\nCfz\t\nclofazimine\nCHW\t\ncommunity health worker\nCI\t\nconfidence interval\nCNS\t\ncentral nervous system\nCONTACT\t\nCommunity Intervention for Tuberculosis Active Contact Tracing and Preventive Therapy\nCOVID-19\t\ncoron",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A list of abbreviations used in the child and adolescent TB handbook, mostly TB and HIV medicines, tests and programme terms.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352523/blocks/prose-sec-002",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Definitions",
      "pageStart": 15,
      "pageEnd": 21,
      "target": "../sections/sec-002-definitions.md",
      "narrative": null,
      "content": "Unless otherwise specified, the terms defined here apply as used in this operational handbook. They \nmay have different meanings in other contexts.\nActive (tuberculosis) case-finding: Provider-initiated screening and testing in communities by \nmobile teams, often using mobile X-ray and rapid molecular tests. The term is sometimes used \nsynonymously with “systematic screening”.\nAdherence: Extent to which a person’s behaviour (e.g. taking medicines, following a particular diet, \nchanging lifestyle) corresponds with agreed recommendations from a health care provider.\nAdvanced HIV disease: For ado",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Defines key terms used in the child and adolescent TB operational handbook, such as active case-finding, adherence, advanced HIV disease and adverse events. It goes on through diagnostic, treatment, disease severity and programme terms, ending with definitions of treatment outcomes, the tuberculin skin test and TB disease. Footnotes cite WHO reporting frameworks and outcome definitions.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352523/blocks/prose-sec-003",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Introduction",
      "pageStart": 21,
      "pageEnd": 21,
      "target": "../sections/sec-003-1-introduction.md",
      "narrative": null,
      "content": "1. Introduction",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A heading for chapter 1, the introduction.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352523/blocks/prose-sec-004",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Background",
      "pageStart": 21,
      "pageEnd": 21,
      "target": "../sections/sec-004-11-background.md",
      "narrative": null,
      "content": "Tuberculosis (TB) is a preventable and curable disease, but it continues to impact the lives and \ndevelopment of millions of children and adolescents. Children and young adolescents aged under \n15 years represent about 11% of all TB cases globally. This means 1.1 million children and young \nadolescents aged under 15 years fall ill with TB every year (1).\nNational tuberculosis programmes (NTPs) notify less than half of these children, and there is a large \ncase detection gap of children who are not diagnosed and/or not reported. The gap is largest in \nchildren aged under 5 years. Reasons for th",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Notes that children and young adolescents under 15 make up about 11% of TB cases, or 1.1 million a year, but fewer than half are notified, with the largest gap in children under 5 owing to diagnostic difficulties. It introduces the 2022 consolidated guidelines and defines a child as under 10 and an adolescent as 10–19 years.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352523/blocks/prose-sec-005",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Children and adolescents as a key vulnerable population",
      "pageStart": 21,
      "pageEnd": 22,
      "target": "../sections/sec-005-12-children-and-adolescents-as-a-key-vulnerable.md",
      "narrative": null,
      "content": "population\nChildren can present with TB disease at any age, but most commonly between the ages of 1 and \n4 years in high TB burden settings. Children who develop TB disease usually do so within a year of \nTB infection. The presentation of TB in children is an indicator of recent and ongoing transmission of \nMycobacterium tuberculosis in the community (4).\nInfants and young children, especially those aged under 2 years, are at higher risk of developing \ndisseminated disease and tuberculosis meningitis (TBM), which are associated with high morbidity and \nmortality (4). Adolescents with TB usuall",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that TB in children is most common at ages 1–4, usually follows recent infection and signals ongoing community transmission, that infants face high risk of severe disease, and that adolescents often have adult-type disease and particular psychosocial needs.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352523/blocks/prose-sec-006",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Rationale and objectives of this operational handbook",
      "pageStart": 22,
      "pageEnd": 22,
      "target": "../sections/sec-006-13-rationale-and-objectives-of-this-operational.md",
      "narrative": null,
      "content": "handbook\nThe aim of this operational handbook is to provide practical guidance on the implementation of the \nWorld Health Organization (WHO) policy recommendations on the prevention and management \nof TB in children and adolescents under programmatic circumstances and at different levels of the \nhealth system.\nThe practical guidance aims to inform the development or revision of national policies and related \nimplementation guidance (e.g. handbooks, standard operating procedures) on the management of \nTB in children and adolescents. This handbook can also help countries adequately plan for the",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "States that the handbook aims to give practical guidance on implementing WHO recommendations on child and adolescent TB and to inform national policies and capacity building. It cites the UN high-level meeting targets for treating children with TB and providing preventive treatment.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352523/blocks/prose-sec-007",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Preferences of end-users regarding content and structure of this operational handbook",
      "pageStart": 22,
      "pageEnd": 23,
      "target": "../sections/sec-007-14-preferences-of-end-users-regarding-content-an.md",
      "narrative": null,
      "content": "structure of this operational handbook\nIn preparation for the development of the WHO consolidated guidelines and operational handbook \non the management of TB in children and adolescents, a survey was conducted among end-users to:\n•\t collect perspectives on the barriers and facilitators for the implementation of WHO recommendations \non the management of TB in children and adolescents;\n•\t understand respondents’ preferences regarding the content and structure of the operational handbook;\n•\t inform dissemination approaches.\nRespondents (N = 182) were from NTPs, United Nations organizations and t",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Reports a survey of 182 end-users on barriers to implementing child TB recommendations and preferences for the handbook, who favoured practical content, translations, electronic versions and dissemination through webinars, regional consultations and online training.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352523/blocks/figure-vfig-p023",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 23,
      "pageEnd": 23,
      "target": "../figures/vfig-p023.webp",
      "narrative": "draft",
      "content": "Pathway diagram of TB exposure, infection and disease drawn as coloured bands: from 'Exposed' to an 'Infected' circle with lungs icon, then branching to 'Accessed health care system' (leading to preventive treatment) or 'Did NOT access health care system' (leading to Diseased, Feeling ill, Accessed health care system, Diagnosed and Treated, with a side branch for 'Un/misdiagnosed'). The render is cropped: the left edge (Susceptible/Exposed) and some stage labels along the top are cut off.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/prose-sec-008",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Structure of the operational handbook",
      "pageStart": 23,
      "pageEnd": 24,
      "target": "../sections/sec-008-15-structure-of-the-operational-handbook.md",
      "narrative": null,
      "content": "The chapters in the handbook are structured around the pathway of TB infection and disease in an \nindividual child or adolescent and the interface with and retention across sequential stages of care \n(cascade of care), as shown in Figure 1.1 (5).\nFigure 1.1. Pathway through TB exposure, infection and disease\nUn/misdiagnosed\nSusceptible\nPreventive treatment\nDiseased\nFeeling ill\nDiagnosed\nTreated\nAccessed health care system\nExposed\nAccessed \nhealth care \nsystem\nInfected\nDid NOT\naccess health \ncare system\nSource: Roadmap towards ending TB in children and adolescents. Geneva: World Health Organiza",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that the handbook follows the pathway from TB exposure to infection, disease, diagnosis and treatment, illustrated in a figure, and describes the chapters and colour-coded boxes for recommendations, key points and examples.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352523/blocks/prose-sec-009",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Target audience",
      "pageStart": 24,
      "pageEnd": 25,
      "target": "../sections/sec-009-16-target-audience.md",
      "narrative": null,
      "content": "The target audience for this handbook includes NTPs and other child health programmes that provide \ncare for children with or at risk of TB, including maternal, newborn, child and adolescent health \nprogrammes, HIV services, and PHC programmes. The handbook also targets paediatricians and \nother health care workers (HCWs) in the public and private sectors, school health services, civil society \nand community-based organizations, and health care educators.",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Identifies the handbook's audience as national TB programmes, child health, HIV and primary care programmes, paediatricians and other health workers, schools, civil society and educators.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352523/blocks/prose-sec-010",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "TB screening and contact investigation",
      "pageStart": 25,
      "pageEnd": 25,
      "target": "../sections/sec-010-2-tb-screening-and-contact-investigation.md",
      "narrative": null,
      "content": "investigation",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A fragment of the chapter 2 heading on TB screening and contact investigation.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352523/blocks/prose-sec-011",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Introduction",
      "pageStart": 25,
      "pageEnd": 26,
      "target": "../sections/sec-011-21-introduction.md",
      "narrative": null,
      "content": "About a quarter of the world’s population has been infected with Mycobacterium tuberculosis. The \nvast majority of these people do not have TB disease (10). It is estimated that 7.5 million children \nand young adolescents aged under 15 years are newly infected with M. tuberculosis each year (11). \nCumulatively, about 67 million children and young adolescents aged under 15 years are infected \nwith M. tuberculosis, including 2 million with MDR-TB and 100 000 with extensively drug-resistant \ntuberculosis (XDR-TB) strains, and therefore at risk of developing TB disease (12). The risk of infection",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Introduces chapter 2, noting that about a quarter of the world's population is infected with TB and that 7.5 million children under 15 are newly infected each year. It defines contact investigation and argues that the case detection gap justifies systematic screening of risk groups.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352523/blocks/figure-vfig-p026",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 26,
      "pageEnd": 26,
      "target": "../figures/vfig-p026.webp",
      "narrative": "draft",
      "content": "Pathway diagram of TB exposure, infection and disease drawn as coloured bands: from 'Exposed' to an 'Infected' circle with lungs icon, then branching to 'Accessed health care system' (leading to preventive treatment) or 'Did NOT access health care system' (leading to Diseased, Feeling ill, Accessed health care system, Diagnosed and Treated, with a side branch for 'Un/misdiagnosed'). A blue circle highlights the stages covered in Chapter 2: Susceptible, Exposed and Infected.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/prose-sec-012",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Contact investigation",
      "pageStart": 26,
      "pageEnd": 37,
      "target": "../sections/sec-012-22-contact-investigation.md",
      "narrative": null,
      "content": "that apply to children and adolescents. It also provides some examples of successful approaches.\nFigure 2.1. Pathway through exposure, infection and disease covered in Chapter 2\nUn/misdiagnosed\nSusceptible\nPreventive treatment\nDiseased\nFeeling ill\nDiagnosed\nTreated\nAccessed health care system\nExposed\nAccessed \nhealth care \nsystem\nInfected\nDid NOT\naccess health \ncare system\nSource: Roadmap towards ending TB in children and adolescents. Geneva: World Health Organization; 2018 (https://apps.who.int/iris/\nhandle/10665/275422).\n2.2. Contact investigation\n2.2.1. Prioritizing household contacts\nHouse",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes contact investigation for children and adolescents, stressing that household and close contacts of people with pulmonary TB should be systematically screened and citing the high risk of disease in infected young children without preventive treatment. It covers prioritising household contacts and planning and budgeting for facility- and community-based approaches. Country examples and boxes describe implementation experiences, including challenges such as reaching remote households and stigma. It ends with prerequisites for a community-based model from the CONTACT study in Uganda and Cameroon.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352523/blocks/figure-vfig-p029",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 29,
      "pageEnd": 29,
      "target": "../figures/vfig-p029.webp",
      "narrative": "draft",
      "content": "Diagram of costing items to strengthen contact investigation (Figure 2.2): five orange steps, each with an arrow listing cost items – identification of contacts (health care workers' time to interview the index TB patient; travel support for household or workplace visits); clinical evaluation (staff time for evaluation and follow-up; enabler or travel support for contacts); testing for TB disease or eligibility for TPT (travel support to the testing site; strengthening specimen collection transport); provide access to TPT (staff time for referral and follow-up); recording and reporting (data capture tools such as the WHO Prevent TB mobile application; staff time).",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/prose-sec-013",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "TB screening approaches in children and adolescents",
      "pageStart": 37,
      "pageEnd": 44,
      "target": "../sections/sec-013-23-tb-screening-approaches-in-children-and-adole.md",
      "narrative": null,
      "content": "adolescents\nScreening serves to identify children and adolescents who may have TB disease (presumptive TB) \nand who need further evaluation to make or confirm a TB diagnosis (see Chapter 4). It also helps to \nidentify children and adolescents who are eligible for and could benefit from TPT. A screening test is \nnot intended to be a diagnostic tool. People with positive results on a screening test should undergo \nfurther diagnostic evaluation.\nChildren and adolescents living with HIV should be systematically screened for TB disease at each \nvisit to a health facility. Child and adolescent house",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains the purpose of TB screening in children and adolescents and when it should be done, such as at every visit for those living with HIV and during contact investigation for household contacts. It describes screening tools, including symptom screening, chest X-ray and rapid molecular tests, and their use by age group. It covers practical considerations for screening child close contacts, including caregiver preferences. It ends by explaining when chest X-ray is needed before starting preventive treatment.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352523/blocks/figure-vfig-p040",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 40,
      "pageEnd": 40,
      "target": "../figures/vfig-p040.webp",
      "narrative": "draft",
      "content": "Flowchart for TB screening of child contacts aged under 15 years using TB symptoms (Figure 2.3). A positive symptom screen leads to 'Refer for diagnostic evaluation including mWRD & clinical evaluation as indicated'; a negative screen leads to 'Negative Screen – Refer for TPT'.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/figure-vfig-p041",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 41,
      "pageEnd": 41,
      "target": "../figures/vfig-p041.webp",
      "narrative": "draft",
      "content": "Flowchart for TB screening of child contacts aged under 15 years using chest X-ray (CXR) (Figure 2.4). A positive CXR leads to 'Refer for diagnostic evaluation including mWRD & clinical evaluation as indicated'; a negative CXR leads to 'Negative Screen – Refer for TPT'.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/figure-vfig-p042",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 42,
      "pageEnd": 42,
      "target": "../figures/vfig-p042.webp",
      "narrative": "draft",
      "content": "Two flowcharts for TB screening of child contacts aged under 15 years. Left (Figure 2.5, parallel screening): TB symptoms and CXR are both assessed; if either or both are positive, the child is referred for diagnostic evaluation including mWRD and clinical evaluation, and if both are negative, 'Negative Screen – Refer for TPT'. Right (Figure 2.6, sequential positive serial screening): children with positive symptoms then have a CXR; a positive CXR leads to diagnostic evaluation, while a negative symptom screen leads to 'Negative Screen – Refer for TPT' and a negative CXR to 'Negative Screen – Explore alternate diagnoses – Refer for TPT'.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/figure-vfig-p043",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 43,
      "pageEnd": 43,
      "target": "../figures/vfig-p043.webp",
      "narrative": "draft",
      "content": "Flowchart for sequential negative serial TB screening of child contacts aged under 15 years (Figure 2.7). Children with positive TB symptoms go directly to diagnostic evaluation including mWRD and clinical evaluation; those with negative symptoms have a CXR, where a positive result also leads to diagnostic evaluation and a negative result to 'Negative Screen – Refer for TPT'.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/figure-vfig-p044",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 44,
      "pageEnd": 44,
      "target": "../figures/vfig-p044.webp",
      "narrative": "draft",
      "content": "Flowchart for TB symptom screening of children living with HIV aged under 10 years (Figure 2.8). A positive symptom screen leads to referral for diagnostic evaluation including mWRD and clinical evaluation; a negative screen leads to 'Negative Screen – Refer for TPT'.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/prose-sec-014",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Screening children and adolescents living with HIV",
      "pageStart": 44,
      "pageEnd": 47,
      "target": "../sections/sec-014-24-screening-children-and-adolescents-living-wit.md",
      "narrative": null,
      "content": "HIV\nChildren living with HIV have a high risk of rapid progression to severe disease and death if a diagnosis \nof TB is missed. A child living with HIV is 3.5 times more likely to progress to TB disease than a child who \nis HIV-negative (29). The risk, although greatly reduced, remains elevated in children on antiretroviral \ntherapy (ART). An estimated 10% of paediatric deaths from TB are among children living with HIV, \nwith 21 000 deaths annually (1). It is for this reason that WHO strongly recommends that children \nliving with HIV are screened for TB.\n2.4.1. Screening for symptoms and conta",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes TB screening of children living with HIV, who are at much higher risk of progression and death, using a symptom and contact screen at every visit with an algorithm and noted sensitivity and specificity. It covers other screening tests, implementation and screening of adolescents, and closes with key points on screening.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352523/blocks/figure-vfig-p047",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 47,
      "pageEnd": 47,
      "target": "../figures/vfig-p047.webp",
      "narrative": "draft",
      "content": "Pathway diagram of TB exposure, infection and disease drawn as coloured bands: from 'Exposed' to an 'Infected' circle with lungs icon, then branching to 'Accessed health care system' (leading to preventive treatment) or 'Did NOT access health care system' (leading to Diseased, Feeling ill, Accessed health care system, Diagnosed and Treated, with a side branch for 'Un/misdiagnosed'). A blue oval highlights the stages covered in Chapter 3: Exposed, Infected, Accessed health care system and Preventive treatment. The left edge of the render is cropped.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/prose-sec-015",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Introduction",
      "pageStart": 47,
      "pageEnd": 47,
      "target": "../sections/sec-015-31-introduction.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-352523/blocks/prose-sec-016",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Prevention of TB in children and adolescents",
      "pageStart": 47,
      "pageEnd": 47,
      "target": "../sections/sec-016-3-prevention-of-tb-in-children-and-adolescents.md",
      "narrative": null,
      "content": "vaccination, TPT and TB infection prevention and control. This chapter relates to the section of the \npathway highlighted in blue in Figure 3.1.\nFigure 3.1. Pathway through exposure, infection and disease covered in Chapter 3\nUn/misdiagnosed\nSusceptible\nPreventive treatment\nDiseased\nFeeling ill\nDiagnosed\nTreated\nAccessed health care system\nExposed\nAccessed \nhealth care \nsystem\nInfected\nDid NOT\naccess health \ncare system\nSource: Roadmap towards ending TB in children and adolescents. Geneva: World Health Organization; 2018 (https://apps.who.int/iris/\nhandle/10665/275422).",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Introduces chapter 3 on preventing TB in children and adolescents through BCG vaccination, preventive treatment and infection control, with a pathway figure.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352523/blocks/prose-sec-017",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "BCG vaccination",
      "pageStart": 47,
      "pageEnd": 52,
      "target": "../sections/sec-017-32-bcg-vaccination.md",
      "narrative": null,
      "content": "BCG is a live attenuated bacterial vaccine derived from Mycobacterium bovis that was originally isolated \nin 1902 from a tuberculous cow. BCG has demonstrated significant effectiveness, but protection has \nnot been consistent against all forms of TB in all age groups. BCG has also shown effectiveness in \npreventing leprosy (caused by Mycobacterium leprae) and Buruli ulcer (caused by Mycobacterium \nulcerans) (31).\nBCG provides good (up to 90%) protection against severe forms of TB, including TBM and miliary TB, \nif given during the neonatal period. Although neonatal vaccination also provides pr",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes BCG vaccine, which gives up to 90% protection against severe TB forms such as meningitis and miliary TB when given at birth and modest protection against infection. It summarises the WHO position paper recommendations on neonatal vaccination in high-burden settings and special groups. It describes local, regional and disseminated adverse events, including BCG-related immune reconstitution syndrome in people with HIV, and their management.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352523/blocks/figure-vfig-p049",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 49,
      "pageEnd": 49,
      "target": "../figures/vfig-p049.webp",
      "narrative": "draft",
      "content": "Line drawing of injection techniques (Figure 3.2): three syringes enter the skin at different angles – intramuscular (vertical, reaching the muscle), subcutaneous (angled, into the subcutaneous layer) and intradermal (almost flat, into the dermis). Layers labelled dermis (skin), subcutaneous layer and muscle. Labels at the right edge are partly cut off.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/figure-img-p050-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 50,
      "pageEnd": 50,
      "target": "../images/img-p050-1.webp",
      "narrative": "draft",
      "content": "Close-up photograph illustrating administration of BCG (Figure 3.3): a hand holds a small syringe whose needle is inserted almost flat into the skin of a child's arm, which rests on white cloth.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/prose-sec-018",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "TB preventive treatment",
      "pageStart": 52,
      "pageEnd": 70,
      "target": "../sections/sec-018-33-tb-preventive-treatment.md",
      "narrative": null,
      "content": "3.3.1. Introduction\nTB infection (previously called latent TB infection) is defined as a “state of persistent immune response \nto stimulation by M. tuberculosis antigens without evidence of TB disease” (15). The number of people \nworldwide estimated to have M. tuberculosis infection is 1.7 billion. Further, 7.5 million children aged \nunder 15 years are estimated to be infected with TB every year (11). By 2014, a cumulative 67 million \nchildren aged under 15 years were infected with TB, including 2 million with MDR-TB and 100 000 \nwith XDR-TB strains (12). People with TB infection have no signs",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Covers TB preventive treatment in children and adolescents, defining TB infection, its global burden and the 5–10% lifetime risk of progression, higher in young children and people with HIV. The headings show it addresses target groups for preventive treatment, ruling out TB disease, testing for infection, the available regimens and child-friendly formulations, and practical implementation. A table explains how to manage missed doses for different regimens such as 3HP and 1HP. It ends by referring other issues, such as babies born to women with TB and ART choice, to other sections and the Module 1 handbook.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352523/blocks/figure-vfig-p058",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 58,
      "pageEnd": 58,
      "target": "../figures/vfig-p058.webp",
      "narrative": "draft",
      "content": "Algorithm for TB infection testing and TB preventive treatment in children and adolescents (Figure 3.4), with three entry groups: HIV positive, household contact and other risk group. People living with HIV are screened for any symptom (current cough, fever, weight loss or night sweats); symptomatic people living with HIV and symptomatic contacts are investigated for TB disease. Asymptomatic contacts under 5 years go to the preventive-treatment decision; those aged 5 years and over and other risk groups have TST or IGRA, then CXR if positive or unavailable (abnormal CXR leads to TB investigation). The decision box 'Preventive treatment contraindicated?' leads to 'Defer' or 'Give preventive treatment', and all paths end with 'Follow up for TB disease as necessary, even for patients who have completed preventive treatment'.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/table-001",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 3.1. TB preventive treatment options",
      "pageStart": 60,
      "pageEnd": 61,
      "target": "../tables/table-3-1.csv",
      "narrative": "draft",
      "content": "TB preventive treatment options for children and adolescents by target group (HIV-negative children by age and weight, children living with HIV, adolescents living with HIV), giving the preferred regimen, alternative regimens and notes on formulations and data gaps.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/table-002",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 3.2. Dosing for recommended TB preventive treatment regimens",
      "pageStart": 62,
      "pageEnd": 63,
      "target": "../tables/table-3-2.csv",
      "narrative": "draft",
      "content": "Doses of the recommended TB preventive treatment regimens (3HR, 3HP, 1HP, 6H or 9H, 4R) by age and body weight. Each regimen gives mg/kg doses by age and, where applicable, nested sub-tables with the number of tablets per weight band for each formulation.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/table-003",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 3.3. Dosing recommendations for use of levofloxacin as TB preventive treatment for drug-resistant TB",
      "pageStart": 64,
      "pageEnd": 64,
      "target": "../tables/table-3-3.csv",
      "narrative": "draft",
      "content": "Levofloxacin doses for 6 months of TB preventive treatment in contacts of people with MDR-TB, by age group (under 15 years, over 14 years) and body weight band.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/table-004",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 3.4. TB preventive treatment completion criteria",
      "pageStart": 67,
      "pageEnd": 67,
      "target": "../tables/table-3-4.csv",
      "narrative": "draft",
      "content": "Completion criteria for each TB preventive treatment regimen (6H, 3HR, 3HP, 1HP, 4R): total duration in months, expected number of doses, the number of doses that makes up 80% of recommended doses, and the extended time allowed for completion (duration plus 33%).",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/prose-sec-019",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "TB infection prevention and control",
      "pageStart": 70,
      "pageEnd": 73,
      "target": "../sections/sec-019-34-tb-infection-prevention-and-control.md",
      "narrative": null,
      "content": "The End TB Strategy emphasizes the need for prevention across all efforts to end the TB epidemic, \nincluding infection prevention and control in health care services and other high-transmission settings (7). \nInfection prevention and control practices are critical to reduce the risk of M. tuberculosis transmission, \nby reducing the concentration of infectious droplet nuclei in the air and the exposure of susceptible \npeople to such aerosols. Although the recommendations in the WHO guidelines on tuberculosis infection \nprevention and control: 2019 update do not specifically mention children or",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains TB infection prevention and control in health facilities, noting that adolescents can transmit like adults and that poor practices expose children, and that COVID-19 mask use may reduce stigma. It outlines administrative, environmental and respiratory protection measures and closes with key points on prevention.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352523/blocks/figure-vfig-p073",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 73,
      "pageEnd": 73,
      "target": "../figures/vfig-p073.webp",
      "narrative": "draft",
      "content": "Pathway diagram of TB exposure, infection and disease drawn as coloured bands: from 'Exposed' to an 'Infected' circle with lungs icon, then branching to 'Accessed health care system' (leading to preventive treatment) or 'Did NOT access health care system' (leading to Diseased, Feeling ill, Accessed health care system, Diagnosed and Treated, with a side branch for 'Un/misdiagnosed'). A blue oval highlights the stages covered in Chapter 4: Diseased, Feeling ill, Accessed health care system, Diagnosed and Treated. The left edge of the render is cropped.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/prose-sec-020",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Introduction",
      "pageStart": 73,
      "pageEnd": 73,
      "target": "../sections/sec-020-41-introduction.md",
      "narrative": null,
      "content": "Diagnostic evaluation is the step in the care cascade after screening. Children and adolescents who \nscreen positive during contact investigation or at health facility-based screening, and those who \npresent to a health care facility with signs and symptoms of TB and who are identified as having \npresumptive TB must be evaluated further for TB disease.\nThe diagnosis of TB disease is usually made based on careful clinical assessment, supported by \nrelevant tests and investigations. Most young children with TB have paucibacillary disease, meaning \nthey harbour relatively few TB bacilli. Conseque",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Introduces the diagnostic chapter, explaining that children with presumptive TB need careful clinical assessment and that bacteriological confirmation is hard in young children because of few bacilli and difficulty producing sputum.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352523/blocks/prose-sec-021",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "TB diagnostic approaches for children and adolescents",
      "pageStart": 73,
      "pageEnd": 74,
      "target": "../sections/sec-021-4-tb-diagnostic-approaches-for-children-and-adol.md",
      "narrative": null,
      "content": "with drug-susceptible TB, DR-TB, PTB and EPTB. PTB is the most common type of TB in children and \nadolescents. in children usually involves disease in the intrathoracic lymph nodes, but in adolescents \nit more commonly resembles adult-type disease with cavitary lesions (4, 6). This chapter relates to \nthe section of the pathway highlighted in blue in Figure 4.1.\nFigure 4.1. Pathway through exposure, infection and disease covered in Chapter 4\nUn/misdiagnosed\nSusceptible\nPreventive treatment\nDiseased\nFeeling ill\nDiagnosed\nTreated\nAccessed health care system\nExposed\nAccessed \nhealth care \nsystem",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Notes that the diagnostic chapter covers drug-susceptible, drug-resistant, pulmonary and extrapulmonary TB, with pulmonary TB in children usually involving chest lymph nodes, and shows a pathway figure.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352523/blocks/prose-sec-022",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Diagnosing TB in children and adolescents",
      "pageStart": 74,
      "pageEnd": 74,
      "target": "../sections/sec-022-42-diagnosing-tb-in-children-and-adolescents.md",
      "narrative": null,
      "content": "Young children have a higher risk of developing TB compared with other age groups (4). Risk of TB \ndisease is more pronounced among children and adolescents who:\n•\t are a household or other close contact with a person with PTB, especially if bacteriologically confirmed;\n•\t are aged under 5 years;\n•\t are living with HIV, especially if poorly controlled;\n•\t have severe acute malnutrition (SAM), especially if not responding to nutritional rehabilitation;\n•\t are hospitalized with pneumonia, especially if not responding to antibiotic treatment.\nDiagnosing TB in children and adolescents relies on a",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists the groups of children and adolescents at highest risk of TB disease, such as close contacts, under-fives and those with HIV or severe malnutrition, from the WHO operational handbook on TB in children and adolescents. It sets out the components of diagnosis, including history, examination, HIV testing, bacteriological testing and chest X-ray, and advises against a trial of TB treatment as a diagnostic method.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352523/blocks/prose-sec-023",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Diagnostic approaches: pulmonary TB",
      "pageStart": 74,
      "pageEnd": 99,
      "target": "../sections/sec-023-43-diagnostic-approaches-pulmonary-tb.md",
      "narrative": null,
      "content": "PTB refers to any bacteriologically confirmed or clinically diagnosed case of TB involving the \nlung parenchyma or tracheobronchial tree. Tuberculous mediastinal and/or hilar intrathoracic \nlymphadenopathy is also classified as PTB, following an expert consultation convened by WHO in \nSeptember 2021.15 Miliary TB is classified as PTB because there are lesions in the lungs. Tuberculous \npleural effusion without radiographic abnormalities in the lungs constitutes EPTB. A person with both \nPTB and EPTB should be classified as having PTB (71).\n4.3.1. Typical symptoms of pulmonary TB\nIn most cases,",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Defines pulmonary TB in children, including intrathoracic lymph node and miliary disease, and describes typical persistent symptoms, cough patterns and the importance of a TB contact history. It covers clinical examination signs suggestive of pulmonary and extrapulmonary TB and considerations during contact investigation. The section goes on to cover diagnostic tests and treatment decision algorithms for children who cannot be confirmed bacteriologically. It ends with an example of scoring under Algorithm B and definitions of the symptoms used in the algorithms, such as cough, fever, weight loss and tachycardia.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352523/blocks/figure-vfig-p075",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 75,
      "pageEnd": 75,
      "target": "../figures/vfig-p075.webp",
      "narrative": "draft",
      "content": "Line chart of differentiated cough patterns (Figure 4.2): intensity of cough (no scale) against duration in weeks (0–4). 'Acute cough with delayed recovery' (dotted red) peaks around week 1 and then declines; 'Recurrent acute cough' (dashed blue) shows two separate peaks near weeks 0.7 and 2.4; 'Persistent, non-remitting cough' (solid orange) rises steadily over 4 weeks. Below are a note on persistent cough (88.9% associated with TB in the cited study), the source, and the start of Box 4.1 listing common symptoms of TB in children.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/figure-img-p077-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 77,
      "pageEnd": 77,
      "target": "../images/img-p077-1.webp",
      "narrative": "draft",
      "content": "WHO Child Growth Standards chart 'Weight-for-age GIRLS, Birth to 5 years (z-scores)' on a pink background. Weight (kg, about 2 to 30) is plotted against age (completed months and years, birth to 5 years), with curved z-score lines labelled 3, 2, 0, −2 and −3 that rise with age.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/figure-vfig-p077",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 77,
      "pageEnd": 77,
      "target": "../figures/vfig-p077.webp",
      "narrative": "draft",
      "content": "Page render with two text boxes (weight loss or failure to thrive; other causes of chronic lung disease) above Figure 4.3, 'Examples of abnormal growth curves': a WHO weight-for-age chart for girls (birth to 5 years, z-score lines 3, 2, 0, −2, −3) with two plotted cases. Case 1, a girl aged 14 months, grew just below the +3 z-score line and then flattened, about 4 kg below her expected weight; case 2, a girl aged 2 years 7 months, grew along the +2 line and then had a static weight for 5 months, about 2 kg below expected.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/figure-img-p078-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 78,
      "pageEnd": 78,
      "target": "../images/img-p078-1.webp",
      "narrative": "draft",
      "content": "WHO Child Growth Standards chart 'Weight-for-age BOYS, Birth to 5 years (z-scores)' on a blue background. Weight (kg, about 2 to 28) is plotted against age (completed months and years, birth to 5 years), with curved z-score lines labelled 3, 2, 0, −2 and −3 that rise with age.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/table-005",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 4.1. WHO-approved respiratory samples for diagnosis of pulmonary TB",
      "pageStart": 80,
      "pageEnd": 80,
      "target": "../tables/table-4-1.csv",
      "narrative": "draft",
      "content": "Compares the WHO-approved respiratory sample types for diagnosing pulmonary TB in children (expectorated sputum, induced sputum, gastric aspirate, nasopharyngeal aspirate, stool) by advantages, disadvantages and caregiver acceptability.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/table-006",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 4.2. Diagnostic accuracy of Xpert MTB/RIF and Ultra in paediatric specimen types against a microbiological reference standarda",
      "pageStart": 81,
      "pageEnd": 81,
      "target": "../tables/table-4-2.csv",
      "narrative": "draft",
      "content": "Sensitivity, specificity and certainty of evidence of Xpert MTB/RIF and Xpert Ultra in children for each specimen type (sputum, gastric aspirate, nasopharyngeal aspirate, stool), against a microbiological reference standard.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/table-007",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 4.3. Commonly used stool processing methods to detect TB using a molecular WHO rapid diagnostic test (see web Annex 4)",
      "pageStart": 82,
      "pageEnd": 82,
      "target": "../tables/table-4-3.csv",
      "narrative": "draft",
      "content": "Side-by-side description of two stool processing methods for molecular TB testing, optimized sucrose floatation and the Simple One-step (SOS) method, covering sample preparation, the processing step and aerosol risk.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/table-008",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 4.4. Summary of WHO-recommended rapid diagnostic tests and specimen types that can be used with them for diagnosis of TB in children and adolescents",
      "pageStart": 85,
      "pageEnd": 85,
      "target": "../tables/table-4-4.csv",
      "narrative": "draft",
      "content": "WHO-recommended rapid diagnostic tests for TB in children and adolescents (Xpert MTB/RIF, Xpert Ultra, Truenat MTB and MTB Plus, TB-LAMP, LF-LAM), listing the specimen types each can be used with and whether it detects rifampicin resistance.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/figure-vfig-p093",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 93,
      "pageEnd": 93,
      "target": "../figures/vfig-p093.webp",
      "narrative": "draft",
      "content": "Treatment decision algorithm for children with presumptive pulmonary TB (Figure 4.4, Algorithm A). It starts with danger signs (stabilize and/or transfer), then children under 2 years, living with HIV and/or with severe acute malnutrition go straight to specimen collection for mWRD testing (e.g. Xpert MTB/RIF or Ultra) and urine LF-LAM, while others are first treated for the most likely non-TB condition and followed up in 1–2 weeks. If mWRD or LF-LAM detects Mycobacterium tuberculosis, or there was close or household TB contact in the previous 12 months, appropriate TB treatment is initiated; otherwise signs and symptoms and CXR features are scored (e.g. cough longer than 2 weeks +2, fever longer than 2 weeks +5, enlarged lymph nodes on CXR +17, miliary pattern +15, tachypnoea −1), and TB treatment is started if Sum A + Sum B > 10, or the child is followed up in 1–2 weeks.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/figure-vfig-p094",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 94,
      "pageEnd": 94,
      "target": "../figures/vfig-p094.webp",
      "narrative": "draft",
      "content": "Treatment decision algorithm for children with presumptive pulmonary TB (Figure 4.5, Algorithm B). It starts with danger signs (stabilize and/or transfer), then children under 2 years, living with HIV and/or with severe acute malnutrition go straight to specimen collection for mWRD testing (e.g. Xpert MTB/RIF or Ultra) and urine LF-LAM, while others are first treated for the most likely non-TB condition and followed up in 1–2 weeks. If mWRD or LF-LAM detects Mycobacterium tuberculosis, or there was close or household TB contact in the previous 12 months, appropriate TB treatment is initiated; otherwise signs and symptoms alone are scored (e.g. cough longer than 2 weeks +5, fever longer than 2 weeks +10, haemoptysis +9, swollen lymph nodes +7, tachypnoea +2), and TB treatment is started if the sum is > 10, or the child is followed up in 1–2 weeks.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/table-009",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 4.5. Danger and priority signs of severe illness or health problems in children aged under 10 years",
      "pageStart": 95,
      "pageEnd": 95,
      "target": "../tables/table-4-5.csv",
      "narrative": "draft",
      "content": "Danger signs for children aged under 5 years (IMCI) and aged 5–9 years (ETAT), grouped as gastrointestinal/circulatory, respiratory and neurological, alongside priority signs for all children aged under 10 years.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/prose-sec-024",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Diagnostic approaches: extrapulmonary TB",
      "pageStart": 99,
      "pageEnd": 102,
      "target": "../sections/sec-024-44-diagnostic-approaches-extrapulmonary-tb.md",
      "narrative": null,
      "content": "EPTB refers to any bacteriologically confirmed or clinically diagnosed case of TB involving organs other \nthan the lungs (e.g. pleura, peripheral lymph nodes, abdomen, genitourinary tract, skin, joints and \nbones, meninges) (71). The classification of intrathoracic lymphadenopathy in children was updated \nfollowing an expert consultation in September 2021 as PTB. EPTB is common in young children \nand in children and adolescents living with HIV. Since it is more difficult to diagnose, children with \npresumed EPTB, especially those who are very ill, should be urgently evaluated or referred for f",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Defines extrapulmonary TB in children and notes it is common in young children and those with HIV, calling for urgent evaluation or referral of very ill children. It reproduces WHO recommendations on using Xpert MTB/RIF and Ultra on non-respiratory specimens such as CSF, lymph node aspirates and blood. A table lists typical presentations and investigations for different extrapulmonary sites, such as TB meningitis, miliary and abdominal TB.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352523/blocks/table-010",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 4.6. Typical clinical features of extrapulmonary TB and suggested investigations",
      "pageStart": 101,
      "pageEnd": 102,
      "target": "../tables/table-4-6.csv",
      "narrative": "draft",
      "content": "Forms of extrapulmonary TB in children, grouped as common forms, forms usually seen in severely ill children under 5 years with disseminated disease, and forms usually seen in children aged 5 years and over. For each site the table gives the typical clinical presentation and suggested investigations.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/prose-sec-025",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Disease severity",
      "pageStart": 102,
      "pageEnd": 103,
      "target": "../sections/sec-025-45-disease-severity.md",
      "narrative": null,
      "content": "In children and adolescents, severity of TB disease ranges from mild to severe. Children with non-\nsevere, drug-susceptible TB are now eligible to receive a shortened 4-month treatment regimen. \nFor consideration of a 4-month treatment regimen for non-severe, drug-susceptible PTB in children \nand young adolescents aged 3 months to 16 years, non-severe TB is defined based on the clinical \npresentation of disease as assessed through physical examination and CXR. All children who have a \ndecision to treat for PTB based on the treatment decision algorithms should be assessed for disease \nseverity.",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains how TB disease severity is assessed in children, since those aged 3 months to 16 years with non-severe drug-susceptible TB can receive a shorter 4-month regimen. It defines non-severe disease by clinical and chest X-ray findings and stresses that assessing severity should not delay treatment.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352523/blocks/prose-sec-026",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Diagnostic approaches: drug-resistant TB",
      "pageStart": 103,
      "pageEnd": 107,
      "target": "../sections/sec-026-46-diagnostic-approaches-drug-resistant-tb.md",
      "narrative": null,
      "content": "The clinical presentation of DR-TB in a child or adolescent is similar to that of other forms of TB in a child \nor adolescent. When DR-TB is suspected, it is important to collect respiratory samples (stool, expectorated \nor induced sputum, NPA sample or gastric aspirate) for bacteriological confirmation by Xpert MTB/RIF or \nXpert Ultra when possible. Truenat MTB or MTB Plus may also be used for sputum specimens. Xpert and \nTruenat assays provide rapid information that indicates rifampicin resistance and therefore DR-TB. Culture-\nbased phenotypic DST, rapid, low-complexity automated nucleic aci",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes how to diagnose drug-resistant TB in children, emphasizing collection of respiratory or stool samples for rapid molecular tests that detect rifampicin resistance and the role of source-case information. It reproduces WHO recommendations on molecular tests for resistance to isoniazid, fluoroquinolones and other drugs. Key messages stress prioritizing bacteriological testing for all children with presumed TB.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352523/blocks/figure-vfig-p107",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 107,
      "pageEnd": 107,
      "target": "../figures/vfig-p107.webp",
      "narrative": "draft",
      "content": "Pathway diagram of TB exposure, infection and disease drawn as coloured bands: from 'Exposed' to an 'Infected' circle with lungs icon, then branching to 'Accessed health care system' (leading to preventive treatment) or 'Did NOT access health care system' (leading to Diseased, Feeling ill, Accessed health care system, Diagnosed and Treated, with a side branch for 'Un/misdiagnosed'). A blue oval highlights the stages covered in Chapter 5: Diagnosed and Treated. The left edge and parts of the top labels are cropped.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/prose-sec-027",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents",
      "pageStart": 107,
      "pageEnd": 107,
      "target": "../sections/sec-027-5-treatment-of-drug-susceptible-and-drug-resista.md",
      "narrative": null,
      "content": "and drug-resistant pulmonary \nand extrapulmonary TB in \nchildren and adolescents",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A chapter title fragment on treating both drug-susceptible and drug-resistant TB, pulmonary and extrapulmonary, in young people.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352523/blocks/prose-sec-028",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Introduction",
      "pageStart": 107,
      "pageEnd": 108,
      "target": "../sections/sec-028-51-introduction.md",
      "narrative": null,
      "content": "This chapter summarizes the treatment options available for children and adolescents to treat drug-\nsusceptible TB and DR-TB and pulmonary and extrapulmonary forms of TB (including TBM), and \nconsiderations related to post-TB health. It includes operational guidance on various new treatment \napproaches, including a 4-month treatment regimen, and important implementation considerations such \nas availability of child-friendly formulations and access to all key medicines for the treatment of DR-TB.\nTreatment outcomes for children completing TB treatment are generally excellent. The vast majority",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Introduces the treatment chapter, which covers regimens for drug-susceptible and drug-resistant TB, TB meningitis and post-TB health, including the new 4-month regimen. It notes that treatment outcomes in children are generally excellent and that most child TB deaths occur in those never treated, with a figure illustrating the cascade from exposure to treatment.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352523/blocks/prose-sec-029",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Treatment of drug-susceptible TB in children and adolescents",
      "pageStart": 108,
      "pageEnd": 135,
      "target": "../sections/sec-029-52-treatment-of-drug-susceptible-tb-in-children.md",
      "narrative": null,
      "content": "adolescents\n5.2.1. Principles of TB management\nTo achieve the goals of successful TB treatment in children and adolescents, clinical and programmatic \nmanagement should include the following components and skills:\n•\t management of TB medicines;\n•\t recognizing clinical signs indicating the need for urgent care;\n•\t managing comorbidities, including undernutrition;\n•\t managing adverse events;\n•\t implementing infection control practices;\n•\t educating patients and their families and caregivers;\n•\t providing psychological and socioeconomical support;\n•\t involving family members in decisions regardin",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Sets out the principles of managing drug-susceptible TB in children and adolescents, from medicine management and comorbidities to family involvement, adherence support and recording. It describes the recommended regimens, including the 4-month regimen for non-severe TB based on the SHINE trial, the rifapentine–moxifloxacin regimen for adolescents aged 12 and over, and a 6-month intensive regimen for TB meningitis. It also covers child-friendly fixed-dose formulations, dose adjustment as children gain weight, adverse events and monitoring. Key messages summarize these points and require all children treated for TB to be registered and reported to the national TB programme.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352523/blocks/table-011",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 5.1. Pulmonary TB treatment regimens by age group, disease severity and local epidemiology",
      "pageStart": 111,
      "pageEnd": 111,
      "target": "../tables/table-5-1.csv",
      "narrative": "draft",
      "content": "Treatment regimens for pulmonary TB by age group (infants under 3 months, children 3 months to under 12 years, adolescents 12–<16 and 16–<20 years) and disease severity, giving the intensive-phase and continuation-phase regimens.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/table-012",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 5.2. Treatment regimens for extrapulmonary TB",
      "pageStart": 117,
      "pageEnd": 117,
      "target": "../tables/table-5-2.csv",
      "narrative": "draft",
      "content": "Treatment regimens for extrapulmonary TB by age group and type (peripheral lymph node TB, other EPTB, TB meningitis, osteoarticular TB), giving intensive-phase and continuation-phase regimens; the 6-month intensive TBM regimen has no separate continuation phase.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/table-013",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 5.3. Recommended dosages of first-line TB medicines for use in children and young adolescents aged 0–14 years (excluding TB meningitis treated with alternative short intensive regimen)",
      "pageStart": 118,
      "pageEnd": 118,
      "target": "../tables/table-5-3.csv",
      "narrative": "draft",
      "content": "Recommended dose and dose range in mg/kg body weight for the four first-line TB medicines (isoniazid, rifampicin, pyrazinamide, ethambutol) in children and young adolescents aged 0–14 years.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/table-014",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 5.4. Recommended interim dosing for the 6-month intensive regimen (6HRZEto) to treat drug-susceptible TB meningitis in children and adolescents",
      "pageStart": 119,
      "pageEnd": 119,
      "target": "../tables/table-5-4.csv",
      "narrative": "draft",
      "content": "Interim dose ranges in mg/kg body weight for the four medicines of the 6-month intensive regimen (6HRZEto) for drug-susceptible TB meningitis in children and adolescents.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/table-015",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 5.5. Dosing table for first-line medicines (excluding the short intensive TBM regimen)",
      "pageStart": 120,
      "pageEnd": 120,
      "target": "../tables/table-5-5.csv",
      "narrative": "draft",
      "content": "Number of child-friendly tablets of first-line TB medicines per weight band: HRZ 50/75/150 mg and ethambutol 100 mg in the intensive phase and HR 50/75 mg in the continuation phase; adult dosages are recommended from 25 kg.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/table-016",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 5.7. Recommended dosage by weight for children and adolescents weighing over 25 kg using adult fixed-dose combinations (excluding the short intensive TB meningitis regimen)",
      "pageStart": 123,
      "pageEnd": 123,
      "target": "../tables/table-5-7.csv",
      "narrative": "draft",
      "content": "Number of adult fixed-dose combination tablets (HRZE 75/150/400/275 mg and HR 75/150 mg) by weight band for children and adolescents weighing over 25 kg.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/table-017",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 5.8. Recommended dosage by weight for adolescents being treated with the 4-month HPZM regimen",
      "pageStart": 123,
      "pageEnd": 123,
      "target": "../tables/table-5-8.csv",
      "narrative": "draft",
      "content": "Doses by weight band for adolescents on the 4-month 2HPMZ/2HPM regimen: isoniazid, rifapentine and moxifloxacin doses are the same for all weight bands in both phases, while the pyrazinamide dose (intensive phase only) varies by weight.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/table-018",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 5.10. Management of treatment interruption in children and adolescents on drug-susceptible TB treatment",
      "pageStart": 132,
      "pageEnd": 132,
      "target": "../tables/table-5-10.csv",
      "narrative": "draft",
      "content": "How to manage interruptions of drug-susceptible TB treatment in children and adolescents, by treatment phase (intensive phase, continuation phase of the 4-month and 6-month regimens) and by the length of the interruption and proportion of doses completed.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/prose-sec-030",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Treatment of multidrug-resistant and rifampicin-resistant TB in children and adolescents",
      "pageStart": 135,
      "pageEnd": 152,
      "target": "../sections/sec-030-53-treatment-of-multidrug-resistant-and-rifampic.md",
      "narrative": null,
      "content": "resistant TB in children and adolescents\nThis section describes a practical approach to the treatment of children with rifampicin-resistant \ntuberculosis (RR-TB) and MDR-TB (resistant to both rifampicin and isoniazid). It covers identifying \nchildren who should be treated for MDR/RR-TB, deciding on the most appropriate treatment regimen, \nmonitoring, and other implementation issues related to treatment.\n5.3.1. Identifying children who should be treated for \nmultidrug-resistant and rifampicin-resistant TB\nBased on modelling estimates, between 25 000 and 32 000 children and young adolescents age",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the practical treatment of children with multidrug- and rifampicin-resistant TB, starting with estimates that tens of thousands of children develop MDR-TB each year yet few are diagnosed. It presents the WHO drug groupings and recommendations favouring the shorter all-oral bedaquiline regimen or individualized longer regimens, now with bedaquiline and delamanid allowed at all ages. It covers monitoring, adverse events and implementation issues. Key messages call for specimen collection, empirical treatment based on the source case, child-friendly formulations, avoiding injectables and social support for families.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352523/blocks/table-019",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 5.11. WHO drug groupings",
      "pageStart": 137,
      "pageEnd": 137,
      "target": "../tables/table-5-11.csv",
      "narrative": "draft",
      "content": "WHO grouping of medicines used in longer MDR/RR-TB regimens into Groups A, B and C, with each drug's abbreviation.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/figure-vfig-p140",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 140,
      "pageEnd": 140,
      "target": "../figures/vfig-p140.webp",
      "narrative": "draft",
      "content": "Grid showing TB medicines and duration of treatment for the standardized all-oral bedaquiline-containing shorter regimen (Figure 5.2), under the regimen notation '4–6 Bdq(6) – Lfx – Cfz – Z – E – Hh – Eto / 5 Lfx – Cfz – Z – E'. Rows are medicines and columns months 1–11: bedaquiline is orange for months 1–6; high-dose isoniazid and ethionamide/prothionamide are orange for months 1–4 and blue for months 5–6; levofloxacin, clofazimine, pyrazinamide and ethambutol are orange for months 1–9 and blue for months 10–11.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/table-020",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 5.12. Possible individualized multidrug-resistant and rifampicin-resistant TB treatment regimens for children of all ages and adolescents, by fluoroquinolone resistance and disease severity",
      "pageStart": 143,
      "pageEnd": 143,
      "target": "../tables/table-5-12.csv",
      "narrative": "draft",
      "content": "Possible individualized MDR/RR-TB regimens for children and adolescents according to fluoroquinolone susceptibility (susceptible, resistant, or resistant also to bedaquiline with or without clofazimine), with the core regimen and additional medicines that may be added.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/table-021",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 5.13. Cerebrospinal fluid penetration of TB medicines used for treatment of multidrug-resistant and rifampicin-resistant TB",
      "pageStart": 144,
      "pageEnd": 144,
      "target": "../tables/table-5-13.csv",
      "narrative": "draft",
      "content": "Groups TB medicines used for MDR/RR-TB by how well they penetrate the cerebrospinal fluid: good, poor except with meningeal inflammation, poor, or limited data.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/table-022",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 5.14. Adverse effects of medicines used for multidrug-resistant and rifampicin-resistant TB by group",
      "pageStart": 147,
      "pageEnd": 149,
      "target": "../tables/table-5-14.csv",
      "narrative": "draft",
      "content": "Main adverse effects of each medicine used for MDR/RR-TB, grouped by WHO Group A, B and C and other medicines (high-dose isoniazid, amoxicillin-clavulanate, pretomanid).",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/prose-sec-031",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Practical guidance for assessment and management of post-TB health in children and adolescents",
      "pageStart": 152,
      "pageEnd": 157,
      "target": "../sections/sec-031-54-practical-guidance-for-assessment-and-managem.md",
      "narrative": null,
      "content": "management of post-TB health in children and \nadolescents\n5.4.1. Post-TB health\nAwareness of the consequences of TB disease in children and adolescents that go beyond survival and \ncompletion of treatment has increased (131, 132). Each child or adolescent on TB treatment should \nbe assigned a mutually exclusive treatment outcome at the end of treatment, but follow-up and care \nmay need to go beyond the conclusion of TB treatment (71). There is also a need to quantify and \nmonitor the burden of morbidity that occurs after TB treatment has been completed (post-TB health). \nImproved data on post-",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Introduces post-TB health in children and adolescents, noting that consequences of TB can persist after treatment and need to be measured and managed. It describes long-term complications of TB meningitis, such as neurodisability, blindness and hormonal problems, with an end-of-treatment assessment table. It also covers assessment of post-TB lung disease using imaging and spirometry and tools for measuring health-related quality of life in children.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352523/blocks/table-023",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 5.15. End-of-treatment clinical assessment in children with TB meningitis",
      "pageStart": 154,
      "pageEnd": 154,
      "target": "../tables/table-5-15.csv",
      "narrative": "draft",
      "content": "Post-treatment assessments for children who have completed treatment for TB meningitis, listed by the specialist responsible (neurologist, physiotherapist and occupational therapist, speech therapist, surgeon and gastrointestinal specialist, endocrinologist).",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/table-024",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 5.16. End-of-treatment assessment of post-TB lung disease in children",
      "pageStart": 155,
      "pageEnd": 155,
      "target": "../tables/table-5-16.csv",
      "narrative": "draft",
      "content": "Assessments recommended at the end of treatment to detect post-TB lung disease in children with non-severe and severe pulmonary TB (clinical assessment, chest X-ray, spirometry, health-related quality of life).",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/table-025",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 5.17. Practical guidance to mitigate and assess post-TB morbidity in children with osteoarticular TB",
      "pageStart": 155,
      "pageEnd": 156,
      "target": "../tables/table-5-17.csv",
      "narrative": "draft",
      "content": "Roles of each specialist (clinician, physiotherapist, occupational therapist, dietician) during and after treatment to prevent and assess long-term morbidity in children with osteoarticular TB.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/prose-sec-032",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Models of TB care for children and adolescents",
      "pageStart": 157,
      "pageEnd": 157,
      "target": "../sections/sec-032-6-models-of-tb-care-for-children-and-adolescents.md",
      "narrative": null,
      "content": "and adolescents",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A section heading fragment on models of TB care for children and adolescents.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352523/blocks/prose-sec-033",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Introduction",
      "pageStart": 157,
      "pageEnd": 160,
      "target": "../sections/sec-033-61-introduction.md",
      "narrative": null,
      "content": "In high TB burden countries, the capacity to manage TB in children and adolescents is often centralized \nat the tertiary or secondary level of health care rather than being decentralized at the PHC level where \nchildren and adolescents with TB or TB exposure commonly seek care (5, 157). Care at higher levels \nin the health system is often managed in a vertical, non-integrated way. Children and adolescents \nwith TB may go undetected because of missed opportunities for contact investigation, TB prevention, \ndetection and care, and as a result of weak integration of child and adolescent TB servic",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that TB care for children in high-burden countries is often centralized and poorly integrated with child health, nutrition and HIV services, leading to missed cases and delays. It cites the 2018 Roadmap's key action on community engagement. It then reproduces WHO recommendations on decentralized, family-centred and integrated care and on community-based, lay-provider and video-supported treatment support.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352523/blocks/prose-sec-034",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Decentralized, family-centred, integrated TB services",
      "pageStart": 160,
      "pageEnd": 174,
      "target": "../sections/sec-034-62-decentralized-family-centred-integrated-tb-se.md",
      "narrative": null,
      "content": "services\nDecentralization includes the provision of, access to or capacity for child and adolescent TB services \nat a lower level of the health system than the lowest level where it is currently routinely provided. In \nmost settings, decentralization applies to the district hospital level (first referral level), PHC level or \ncommunity level. Interventions to facilitate decentralization include capacity-building of various cadres \nof HCWs, access to diagnostic services, availability of TB medicines for children and adolescents, and \nfollow-up of children and adolescents with TB or on TPT.\nSinc",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains what decentralizing child and adolescent TB services means and the interventions needed, such as training health workers, access to diagnostics and medicines, and follow-up. It describes a flexible approach for national programmes, health workforce tasks at each level of care in a table, and integration with other child health services. The section includes country examples, such as integrating childhood TB into IMNCI services in Addis Ababa with a sharp rise in contact screening and preventive treatment. It notes that services including gastric aspiration can be decentralized to primary care with supporting packages.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352523/blocks/table-026",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 6.1. Health care workers’ tasks at different levels of care",
      "pageStart": 162,
      "pageEnd": 163,
      "target": "../tables/table-6-1.csv",
      "narrative": "draft",
      "content": "Tasks of health care workers in child and adolescent TB care at three levels of the health system: primary care, first referral level and second referral level.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/table-027",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 6.2. Aspects to consider when planning for the provision of decentralized, family-centred, integrated TB services",
      "pageStart": 164,
      "pageEnd": 165,
      "target": "../tables/table-6-2.csv",
      "narrative": "draft",
      "content": "Planning steps for decentralized, family-centred, integrated TB services for children and adolescents (service mapping, stakeholder analysis, policy review, human resources, resource mapping, access to medicines and supplies, health information), each with a description and rationale.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/table-028",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 6.3. Opportunities for integrating TB services into other services",
      "pageStart": 166,
      "pageEnd": 167,
      "target": "../tables/table-6-3.csv",
      "narrative": "draft",
      "content": "Opportunities to integrate TB services into other health services for five target populations (children; children and adolescents living with HIV; adolescents, girls and young women; pregnant women; postnatal women), with the actions required to deliver TB services through each.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/prose-sec-035",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Private-sector involvement in care for children and adolescents with TB",
      "pageStart": 174,
      "pageEnd": 178,
      "target": "../sections/sec-035-63-private-sector-involvement-in-care-for-childr.md",
      "narrative": null,
      "content": "and adolescents with TB\n6.3.1. Background\nIn many high TB burden countries, the majority of missing people with TB, including children, seek \ntreatment from private providers or other care providers not linked to the public sector at least once \n(174). The private sector is also a common point of care for children presenting with common illnesses, \nsuch as cough, fever and diarrhoea, especially in countries with a large private sector (175). In these \ncountries, people with or at risk of TB are unlikely to access good-quality TB services if the NTP does \nnot comprehensively engage the private",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that many children with TB first seek care from private providers and that national programmes must engage the private sector. It sets out key actions from the WHO public–private mix roadmap applied to child TB, such as mapping providers, setting targets, funding and working with paediatric associations. A case study from India describes linking over 1100 children treated by private providers to free public fixed-dose combinations, with the proportion rising from 29% to 65%. It also notes challenges such as treatment delays, pharmacy hours and pill burden.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352523/blocks/prose-sec-036",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Differentiated TB service delivery",
      "pageStart": 178,
      "pageEnd": 182,
      "target": "../sections/sec-036-64-differentiated-tb-service-delivery.md",
      "narrative": null,
      "content": "6.4.1. Background\nThe concept of DSD (previously referred to as differentiated care) is increasingly being applied during \nthe provision of comprehensive HIV services (78). In the context of HIV, DSD is a people-centred \napproach that simplifies and adapts HIV services to better serve the needs of people living with HIV \nand to optimize the available resources in health systems. DSD is premised on the fact that delivery \nof services is not a one-size-fits-all model but rather recognizes the diversity of people who seek \nthe services. It is designed to efficiently deliver people-centred package",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Introduces differentiated service delivery, a people-centred approach developed for HIV care, and how it can be applied to TB services for children and adolescents. It discusses aligning TB treatment and preventive therapy with multimonth antiretroviral dispensing and family-centred care, while noting risks of fewer screening opportunities. Illustrated examples show models for children receiving TB preventive treatment, such as a child contact of a caregiver with HIV and TB supported by SMS.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352523/blocks/prose-sec-037",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "TB and health emergencies",
      "pageStart": 182,
      "pageEnd": 185,
      "target": "../sections/sec-037-65-tb-and-health-emergencies.md",
      "narrative": null,
      "content": "Health emergencies, such as the COVID-19 pandemic, are associated with a disruption in health \nservice delivery, either directly due to the focused attention given to the emergency or indirectly due \nto measures implemented to control the emergency.\nThe COVID-19 pandemic has reversed years of progress in providing essential TB services and \nreducing the disease burden of TB. There has been a large global drop in the number of people \nnewly diagnosed with TB and reported. The number fell from 7.1 million in 2019 to 5.8 million (out \nof the approximately 10 million people estimated to have devel",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes how health emergencies such as COVID-19 disrupted TB services, citing the fall in notified TB cases from 7.1 million in 2019 to 5.8 million in 2020. It discusses the direct and indirect effects of emergencies on child and adolescent TB services and outlines measures to maintain care. It concludes that mitigation approaches should take account of the particular needs of children and adolescents with or exposed to TB.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352523/blocks/prose-sec-038",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Special situations",
      "pageStart": 185,
      "pageEnd": 185,
      "target": "../sections/sec-038-7-special-situations.md",
      "narrative": null,
      "content": "This chapter covers a range of special situations related to the management of TB in children \nand adolescents:",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Introduces the chapter on special situations in managing TB in children and adolescents.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352523/blocks/prose-sec-039",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Management of TB in children and adolescents living with HIV",
      "pageStart": 185,
      "pageEnd": 196,
      "target": "../sections/sec-039-71-management-of-tb-in-children-and-adolescents.md",
      "narrative": null,
      "content": "•\t Section 7.2: TB in pregnancy and management of newborns of mothers with TB disease;\n•\t Section 7.3: palliative care for children and adolescents with TB;\n•\t Section 7.4: care for adolescents with or at risk of TB;\n•\t Section 7.5: TB in children with pneumonia;\n•\t Section 7.6: management of children with TB and malnutrition.\n7.1. Management of TB in children and adolescents \nliving with HIV\nThis section outlines how to screen for, prevent and manage TB/HIV coinfection in children and \nadolescents living with HIV (CALHIV).\n7.1.1. Introduction\nChildren and adolescents living with HIV have an i",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists the special situations covered in the chapter and opens section 7.1 on TB in children and adolescents living with HIV, who face higher risks of TB infection, disease and death. It covers HIV testing recommendations, TB screening with symptom screening and chest radiography, and prevention through preventive treatment for household contacts. Later parts address treatment and co-management with antiretroviral therapy. It ends with guidance on recognising and managing TB immune reconstitution inflammatory syndrome, including when to continue treatment, use anti-inflammatory drugs or refer.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352523/blocks/table-029",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 7.1. Preferred and alternative first-line antiretroviral therapy regimens for neonates, children and adolescents on TB treatment",
      "pageStart": 192,
      "pageEnd": 192,
      "target": "../tables/table-7-1.csv",
      "narrative": "draft",
      "content": "Preferred, alternative and special-circumstance first-line antiretroviral regimens for neonates, children and adolescents on TB treatment. In the printed table, colour indicates whether each regimen needs no change, a dose adjustment or a change of regimen with TB treatment.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/table-030",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 7.2. Changes needed to antiretroviral therapy regimens for neonates, children and adolescents on drug-susceptible TB treatment",
      "pageStart": 193,
      "pageEnd": 194,
      "target": "../tables/table-7-2.csv",
      "narrative": "draft",
      "content": "Changes needed to each type of antiretroviral regimen when neonates, children or adolescents on ART start drug-susceptible TB treatment, or start ART while on TB treatment, including dose adjustments and regimen substitutions.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/table-031",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 7.3. TB preventive treatment options for children and adolescents on antiretroviral therapy",
      "pageStart": 195,
      "pageEnd": 195,
      "target": "../tables/table-7-3.csv",
      "narrative": "draft",
      "content": "For each TB preventive treatment regimen (6H, 3HP, 3HR, 4R, 1HP, isoniazid–pyridoxine–co-trimoxazole), which antiretroviral medicines are contraindicated, should be used with caution, need dose adjustment, or can be used.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/prose-sec-040",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "TB in pregnancy and management of newborns of mothers with TB disease",
      "pageStart": 196,
      "pageEnd": 199,
      "target": "../sections/sec-040-72-tb-in-pregnancy-and-management-of-newborns-of.md",
      "narrative": null,
      "content": "of mothers with TB disease\nTB contributes to 6–15% of all maternal mortality and leads to adverse pregnancy outcomes (187). \nA national registry study found incidence rate ratios for TB in pregnant and postpartum women of \n1.4 and 1.9, respectively, compared with non-pregnant women (188). TB in pregnancy is associated \nwith adverse maternal outcomes and complications during birth, such as pre-eclampsia, eclampsia, \nvaginal bleeding, hospitalization and miscarriage. Perinatal outcomes include a two-fold increased \nrisk of premature birth, low birthweight and intrauterine growth retardation, and",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the contribution of TB to maternal mortality and adverse pregnancy and perinatal outcomes, and covers TB screening for pregnant women living with HIV with a table of screening tool accuracy. It then addresses diagnosis and management of congenital and neonatal TB. It closes with care for well newborns of mothers with TB, including preventive treatment, referral for MDR/RR-TB exposure and infection control.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352523/blocks/table-032",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 7.4. Diagnostic accuracy of WHO-recommended screening tools in pregnant women living with HIV",
      "pageStart": 197,
      "pageEnd": 197,
      "target": "../tables/table-7-4.csv",
      "narrative": "draft",
      "content": "Sensitivity and specificity, against a culture reference standard, of four WHO-recommended TB screening tools in pregnant women living with HIV: the WHO four-symptom screen (W4SS), C-reactive protein, W4SS combined with chest X-ray, and molecular WHO-recommended rapid diagnostic tests.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/prose-sec-041",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Palliative care for children and adolescents with TB",
      "pageStart": 199,
      "pageEnd": 203,
      "target": "../sections/sec-041-73-palliative-care-for-children-and-adolescents.md",
      "narrative": null,
      "content": "7.3.1. Introduction\nIn 2014, World Health Assembly Resolution WHA67.19 called upon WHO and Member States to \nimprove access to palliative care as a core component of health systems, with an emphasis on PHC \nand community- and home-based care (197). WHO is supporting integration of palliative care into \nall relevant global disease control and health system plans and is promoting improved access to \npalliative care for children, in collaboration with the United Nations Children’s Fund.\n\t\nÎ Assess the newborn. If the newborn is not well, refer to a specialist or paediatrician for \nfurther evaluat",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Covers palliative care for children and adolescents with TB, starting from the 2014 World Health Assembly resolution calling for better access to palliative care. It describes circumstances in which children with TB may need palliative care and actions to make it available. A table gives examples of managing symptoms such as breathlessness and cough in children with advanced lung disease.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352523/blocks/figure-img-p200-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 200,
      "pageEnd": 200,
      "target": "../images/img-p200-1.webp",
      "narrative": "draft",
      "content": "Infographic titled 'What is palliative care?' (Figure 7.1): a stylized tree whose branches point to six statements – it is care for patients with life-threatening illnesses and their families; it can be given in homes, health centres, hospitals and hospices; it improves quality of life; it benefits health systems by reducing unnecessary hospital admissions; it relieves physical, psychosocial and spiritual suffering; it can be done by many types of health professionals and volunteers.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/table-033",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 7.5. Actions to promote accessibility and availability of palliative care for children",
      "pageStart": 202,
      "pageEnd": 202,
      "target": "../tables/table-7-5.csv",
      "narrative": "draft",
      "content": "Actions to make palliative care for children more accessible and available, grouped by area: policy, integration into the health system, training and education, access to essential medicines, research, and awareness.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/prose-sec-042",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Care for adolescents with or at risk of TB",
      "pageStart": 203,
      "pageEnd": 208,
      "target": "../sections/sec-042-74-care-for-adolescents-with-or-at-risk-of-tb.md",
      "narrative": null,
      "content": "Adolescents with TB often present with bacteriologically infectious disease typical in adults (e.g. \ncavities seen on CXR) and therefore pose a high risk for transmission in households and congregate \nsettings such as schools. Adolescents face unique challenges due to peer pressure and fear of stigma, \nincreasing prevalence of comorbidities such as HIV, and risk behaviours such as use of alcohol, tobacco \nand other substances. People aged 10–19 years need adolescent-friendly services that include relevant \npsychosocial support and minimal disruption of education (5).\nAge-disaggregated data on",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the needs of adolescents with TB, who often have infectious adult-type disease and face stigma, peer pressure, comorbidities and risk behaviours. Sections follow a framework of physical and mental health, connectedness, safety and support, education and skills, agency and resilience, and substance use with late presentation to care. Each area sets out actions for adolescent-friendly services. The block ends by calling for collaboration with other sectors on basic needs such as food security and continued schooling.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352523/blocks/table-034",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 7.6. Examples of symptom management for children and adolescents with TB in need of palliative care (207, 208)",
      "pageStart": 203,
      "pageEnd": 203,
      "target": "../tables/table-7-6.csv",
      "narrative": "draft",
      "content": "Recommended management of four respiratory symptoms (dyspnoea, cough, haemoptysis, retained secretions at end of life) in children and adolescents with TB who need palliative care.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/prose-sec-043",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "TB in children with severe acute pneumonia",
      "pageStart": 208,
      "pageEnd": 210,
      "target": "../sections/sec-043-75-tb-in-children-with-severe-acute-pneumonia.md",
      "narrative": null,
      "content": "TB is a common cause or comorbidity in children with clinically diagnosed pneumonia. A systematic \nreview on TB in acute respiratory infection found that M. tuberculosis was identified in around 5–10% of \nchildren with pneumonia aged under 5 years in TB endemic countries (223). Limited data from clinical \nand autopsy studies suggest that TB was also associated with mortality in these children. Prevalence \nstudies, including the multisite PERCH study (224), confirm these findings.\nThe review found that clinical features, including persistence of symptoms, had low specificity for \ndiagnosis of T",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Discusses TB as a cause or comorbidity of severe pneumonia in young children, citing a systematic review finding TB in about 5-10% of under-fives with pneumonia in endemic countries. It notes that clinical features have low specificity, and includes boxes on implications for implementation and findings of the TB-Speed Pneumonia study on Xpert Ultra testing.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352523/blocks/prose-sec-044",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Management of children with TB and malnutrition",
      "pageStart": 210,
      "pageEnd": 217,
      "target": "../sections/sec-044-76-management-of-children-with-tb-and-malnutriti.md",
      "narrative": null,
      "content": "malnutrition\n7.6.1. Introduction\nBy reducing cell-mediated immunity, undernutrition increases the risk of TB, while the catabolic effect \nof TB disease results in weight loss and wasting, creating a vicious cycle (105, 228). Globally, about 45% \nof deaths in children aged under 5 years are attributable to undernutrition (228). Undernutrition may \nbe acute or chronic and categorized as moderate or severe. Data from the 2021 Global Tuberculosis \nReport suggest that 1.9 million TB cases per year (19%) are attributable to undernourishment (1). \nData on TB prevalence among acutely malnourished chil",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains the two-way link between undernutrition and TB in children, citing estimates that about 19% of TB cases are attributable to undernourishment and varied TB prevalence among acutely malnourished children. It covers diagnosis and treatment of TB in malnourished children and nutritional care for children and adolescents with TB. Key points include evaluating children with severe acute malnutrition who fail to gain weight for TB and using a 6-month regimen for them.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352523/blocks/prose-sec-045",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "References",
      "pageStart": 217,
      "pageEnd": 231,
      "target": "../sections/sec-045-8-references.md",
      "narrative": null,
      "content": "1.\t Global tuberculosis report 2021. Geneva: World Health Organization; 2021 (https://apps.who.int/iris/\nhandle/10665/346387, accessed 1 December 2021).\n2.\t Snow KJ, Sismanidis C, Denholm J, et al. The incidence of tuberculosis among adolescents and young adults: \na global estimate. Eur Respir J. 2018;51(2):1702352.\n3.\t WHO consolidated guidelines on tuberculosis. Module 5: management of tuberculosis in children \nand adolescents. Geneva: World Health Organization; 2022 (https://apps.who.int/iris/bitstream/\nhandle/10665/352522/9789240046764-eng.pdf).\n4.\t Marais B. The natural history of childho",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The reference list for the operational handbook on managing TB in children and adolescents, with 230 citations including WHO TB reports and guidelines and studies on paediatric TB, HIV, pregnancy and malnutrition.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352523/blocks/prose-sec-046",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Annex 1. Selected resources on child and adolescent TB",
      "pageStart": 231,
      "pageEnd": 234,
      "target": "../sections/sec-046-annex-1-selected-resources-on-child-and-adolesce.md",
      "narrative": null,
      "content": "Annex 1. Selected resources on \nchild and adolescent TB\nRoadmap\nRoadmap towards ending TB in children and adolescents, second edition. Geneva: World Health \nOrganization; 2018 (https://apps.who.int/iris/bitstream/handle/10665/275422/9789241514798-eng.\npdf?sequence=1&isAllowed=y).\nWHO operational handbooks\nWHO operational handbook on tuberculosis. Module 1: prevention – tuberculosis preventive treatment. \nGeneva: World Health Organization; 2020 (https://www.who.int/publications/i/item/9789240002906).\nWHO operational handbook on tuberculosis. Module 2: screening – systematic screening for \ntuber",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "An annex listing selected resources on child and adolescent TB, including the WHO roadmap, operational handbooks, training materials and research and implementation projects such as TB-Speed.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352523/blocks/prose-sec-047",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Annex 2. Tuberculin skin testing: administration, reading and interpretation",
      "pageStart": 234,
      "pageEnd": 237,
      "target": "../sections/sec-047-annex-2-tuberculin-skin-testing-administration-r.md",
      "narrative": null,
      "content": "administration, reading and \ninterpretation\nThis annex provides information on administering, reading and interpreting tuberculin skin tests (TSTs).\nA TST is the intradermal injection of a combination of mycobacterial antigens that elicit a delayed-type \nhypersensitivity immune response, represented by induration, which can be measured in millimetres.\nThe standard method of identifying people infected with Mycobacterium tuberculosis is the TST using \nthe Mantoux method. Multiple puncture tests should not be used as these tests are unreliable (because \nthe amount of tuberculin injected intrader",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "An annex explaining how to give, read and interpret a tuberculin skin test by the Mantoux method using 5 tuberculin units. It covers the injection technique, measuring induration and thresholds for a positive result. It also discusses causes of false-positive and false-negative results.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352523/blocks/table-035",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table A2.1. Causes of false-negative and false-positive tuberculin skin tests",
      "pageStart": 236,
      "pageEnd": 236,
      "target": "../tables/table-a2-1.csv",
      "narrative": "draft",
      "content": "Lists the causes of false-negative tuberculin skin test results (e.g. HIV, recent infection, severe TB, malnutrition, immunosuppression) alongside the causes of false-positive results (e.g. previous BCG vaccination, non-tuberculous mycobacteria, incorrect administration).",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/prose-sec-048",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Annex 3. Sample collection methods",
      "pageStart": 237,
      "pageEnd": 240,
      "target": "../sections/sec-048-annex-3-sample-collection-methods.md",
      "narrative": null,
      "content": "Annex 3. Sample collection methods\nThis annex provides an overview of respiratory and non-respiratory specimens that can be used to diagnose TB in children and adolescents, with a short \ndescription for each, the age group in which they can be used, the minimum volume required for testing, and the optimal time of collection.\nTable A3.1. Respiratory specimens\nSpecimen\nDescription of procedure\nAge group\nMinimum volume \nfor testinga\nOptimal \ncollection time\nComments\n(Spontaneous) \nexpectorated \nsputum\nExpectoration of sputum \nwithout prior saline \nnebulization\n>5 years\n3 mL\nEarly morning\nIf child",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "An annex describing respiratory and non-respiratory specimens for diagnosing TB in children and adolescents, with tables giving each procedure, suitable age group, minimum volume and best collection time.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352523/blocks/prose-sec-049",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Annex 4. Standard operating procedures for sample collection methods",
      "pageStart": 240,
      "pageEnd": 247,
      "target": "../sections/sec-049-annex-4-standard-operating-procedures-for-sample.md",
      "narrative": null,
      "content": "procedures for sample collection \nmethods\nThis annex provides examples of standard operating procedures for the most common methods of \nobtaining clinical samples from children for rapid molecular testing: expectoration, gastric aspiration, \nnasopharyngeal aspiration (NPA) and sputum induction.\nBiosafety and infection prevention and control \npractices to be followed during cough-inducing and \naerosol-generating procedures\nGastric aspiration, NPA and sputum induction are considered aerosol-generating procedures. Although \nchildren with TB disease are usually less likely than adults to be infect",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "An annex giving standard operating procedures for collecting samples from children for rapid molecular TB testing by expectoration, gastric aspiration, nasopharyngeal aspiration and sputum induction. It opens with biosafety and infection-control precautions for these aerosol-generating procedures, such as dedicated ventilated rooms, respirators and disinfection. Each method then has a background note and step-by-step instructions for preparing the child, carrying out the procedure and handling the specimen. The annex closes with advice on obtaining specimens from young children who cannot expectorate and on sterilizing reusable equipment.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352523/blocks/prose-sec-050",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Annex 5. Treatment decision algorithms",
      "pageStart": 247,
      "pageEnd": 254,
      "target": "../sections/sec-050-annex-5-treatment-decision-algorithms.md",
      "narrative": null,
      "content": "algorithms \nMethodology for developing the treatment decision \nalgorithms\nIndividual-level participant diagnostic evaluations and outcome data in children aged under 10 years \npresenting for evaluation of PTB were solicited from studies carried out in geographically diverse high \nTB burden settings. Missing data were imputed using multiple imputations by chained equations. \nPrediction models were built to classify participants as having TB (confirmed or unconfirmed TB) \nor unlikely TB using features from clinical evaluation and CXR as predictors. The predictors were \nselected based on those co",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "An annex presenting treatment decision algorithms for children under 10 with suspected pulmonary TB, starting with how the scoring models were built from pooled individual patient data and set at 85% sensitivity. It explains the triage steps for danger signs, high-risk children and rapid molecular testing that come before scoring. Two algorithms are shown, one for settings with chest X-ray and one without, assigning points to symptoms and radiographic features with a threshold of more than 10 for starting treatment. Operational guidance follows, including age-specific definitions of signs such as fast breathing and a worked scoring example.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352523/blocks/table-036",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table A5.1. Danger and priority signs of severe illness or health problems in children aged under 10 years",
      "pageStart": 250,
      "pageEnd": 251,
      "target": "../tables/table-a5-1.csv",
      "narrative": "draft",
      "content": "Danger signs for children aged under 5 years (IMCI) and aged 5–9 years (ETAT), grouped as gastrointestinal/circulatory, respiratory and neurological, alongside priority signs for all children aged under 10 years.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352523/blocks/prose-sec-051",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Annex 6. Dosing of medicines used in second-line multidrug-resistant TB regimens by weight band (below 46 kg)a",
      "pageStart": 254,
      "pageEnd": 260,
      "target": "../sections/sec-051-annex-6-dosing-of-medicines-used-in-second-line.md",
      "narrative": null,
      "content": "multidrug-resistant TB regimens by weight band \n(below 46 kg)a\n•\t Dosing guidance is based on currently available data and may be revised once additional data are available.\n•\t For patients weighing ≥46 kg, please refer to Table A in Annex 1 of the WHO operational handbook on tuberculosis. Module 4: treatment – drug-resistant \ntuberculosis: Dosing of medicines used in second-line multidrug-resistant TB regimens by weight band (patients 15 years or older).\n•\t For dosing of premature and low birth weight infants weighing <3 kg, advice from a paediatric DR-TB expert should be sought.\n•\t For dosin",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "An annex tabulating weight-band dosing of second-line medicines for multidrug-resistant TB in children and adolescents under 46 kg, grouped as in WHO regimens. Introductory notes cover preferring child-friendly dispersible tablets, dissolving tablets in water to give measured volumes, and seeking expert advice for infants. The table gives daily doses, formulations and usual maximum doses for drugs such as levofloxacin, moxifloxacin, bedaquiline and linezolid. Footnotes explain special cases, including pyridoxine use and giving carbapenems only with clavulanate.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352523/blocks/prose-sec-052",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Annex 7. Overview of options for neurocognitive and functional testing at end of treatment for TB meningitis",
      "pageStart": 260,
      "pageEnd": 264,
      "target": "../sections/sec-052-annex-7-overview-of-options-for-neurocognitive-a.md",
      "narrative": null,
      "content": "neurocognitive and functional \ntesting at end of treatment for \nTB meningitis\nTable A7.1. Options for neurocognitive and functional testing at end of treatment for TB \nmeningitis\nOutcome\nMeasure\nTiming\nNeurodevelopmental\nMinimal:\n•\tAges and Stages Questionnaire (age range \n0–5 years) a\nOptimal:\n•\tBailey Scale of Infant Development, 3rd \nedition (age range 1–42 months) b\n•\tMullen Scale Early Learning (age range \n0–68 months) c\nPost-acute: 6–9 months, \n2 years, 4 years\nNeurocognitive\n•\tWechsler Intelligence Scales for Children \n(age range 6–16 years) d\n•\tKauffman Assessment Battery for Children,",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "An annex table listing tools and timing for neurodevelopmental, neurocognitive, functional and behavioural testing of children at the end of TB meningitis treatment. It notes that these tools are not adapted for low- and middle-income countries and closes with sources and WHO contact details.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352523/blocks/table-037",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table A7.1. Options for neurocognitive and functional testing at end of treatment for TB meningitis",
      "pageStart": 260,
      "pageEnd": 261,
      "target": "../tables/table-a7-1.csv",
      "narrative": "draft",
      "content": "For each outcome domain after TB meningitis (neurodevelopmental, neurocognitive, functional, neurobehavioural), the table lists minimal and optimal assessment tools with their age ranges and the recommended timing of testing.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    }
  ]
}
